Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry.
Adenocarcinoma of Lung
/ epidemiology
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ epidemiology
Carcinoma, Squamous Cell
/ epidemiology
Chronic Disease
Cohort Studies
Combined Modality Therapy
Czech Republic
/ epidemiology
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ epidemiology
Male
Middle Aged
Prognosis
Registries
/ statistics & numerical data
Survival Rate
2-year survival
Non-small cell lung cancer
chronic disease
modern-era treatment
personalized treatment
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
19
08
2019
revised:
21
09
2019
accepted:
27
09
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
10
6
2020
Statut:
ppublish
Résumé
To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients.
Identifiants
pubmed: 31882501
pii: 34/1/369
doi: 10.21873/invivo.11783
pmc: PMC6984115
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-379Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Lancet Oncol. 2012 Mar;13(3):300-8
pubmed: 22277837
Lung Cancer. 2019 Jan;127:84-89
pubmed: 30642557
Mol Clin Oncol. 2018 Aug;9(2):201-206
pubmed: 30101022
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Value Health. 2015 Sep;18(6):774-82
pubmed: 26409604
Lancet Oncol. 2016 Dec;17(12):1683-1696
pubmed: 27836716
J Clin Oncol. 2004 Mar 15;22(6):1103-9
pubmed: 15020612
Lancet Oncol. 2012 Oct;13(10):1011-9
pubmed: 22954507
Psychooncology. 2010 May;19(5):480-9
pubmed: 19434625
J Psychosoc Oncol. 2008;26(1):69-80
pubmed: 18077263
Lung Cancer. 2005 Mar;47(3):293-300
pubmed: 15713512
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
J Natl Cancer Inst Monogr. 2004;(33):56-77
pubmed: 15504920
JCI Insight. 2018 Aug 9;3(15):
pubmed: 30089719
Psychooncology. 2001 Jan-Feb;10(1):19-28
pubmed: 11180574
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Lancet Oncol. 2016 Apr;17(4):452-463
pubmed: 26973324
J Thorac Oncol. 2014 Feb;9(2):205-13
pubmed: 24419418
Medicine (Baltimore). 2018 Aug;97(33):e11936
pubmed: 30113497
Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9
pubmed: 15961694
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2003 Jun 15;21(12):2237-46
pubmed: 12748244
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Front Public Health. 2016 Aug 02;4:159
pubmed: 27532034
Cancer Res Treat. 2019 Apr;51(2):502-509
pubmed: 29898592
J Thorac Oncol. 2019 Jul;14(7):1233-1243
pubmed: 30902613
Eur J Cancer. 2017 Jun;78:16-23
pubmed: 28407528